2011 was not a good year for the stock prices of stem cell companies. That dropped Aastrom’s price well below fair market valuation. Now momentum seems to be gathering for the stock. Here’s what Henry McCusker, Director of Research at Scimitar Equity, said on Seeking Alpha: “Another interesting statistic is that over the past year, CEO Tim Mayleben has bought
Read more…

Pharmacyclics (PCYC) signed rights to its blood-cancer drug PCI-32765 to Johnson & Johnson (JNJ) for a whopping $150m. This is a big deal for a growing biotech company and ensures that it now has one of the best pharma customers in the world. http://ow.ly/7XH94